World Health Organization Raises Warning Over Acute Lack of Obesity Jabs

Fewer than a tenth of patients that would benefit from GLP-1 drugs such as Wegovy have access to them, states the World Health Organization as it publishes its first guidance on the therapies.

Considering over a billion people worldwide currently living with obesity, it is advocating for broader and more equitable availability to these injectable treatments.

Based on forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.

"The latest guidance affirms that obesity is a long-term condition that can be addressed with comprehensive and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and distribution challenges are major hurdles to broad availability to the jabs that can assist patients in reducing considerable weight, says the organization.

Skinny Jab Supply Crisis

Even in the present best projected outlook, the production of these medications would only suffice for around 100 million people – fewer than 10% of eligible patients, as stated by the WHO.

The advice encourages governments and firms to expand availability, through measures like patent sharing.

The intellectual property rights on a key compound – the primary component of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.

How Weight-Loss Jabs Function

The injections replicate a body's own hormone to slow digestion, curb appetite and boost the sense of being full so people reduce food intake.

People typically start to lose weight in the initial weeks of beginning the regular doses.

Evidence points to people may put most of the weight back on after a year of stopping the medication, when their usual hunger resume.

Being carrying excess weight raises your risk for experiencing diseases, including diabetes, cardiovascular issues, brain attack, and some malignancies.

Obesity impacts people in all nations and was associated with millions of deaths worldwide in 2024, as per the health agency.